The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings, www.benzinga.com

The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings

Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,…

Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.

COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY) GlaxoSmithKline plc (NYSE: GSKwon a joint $2.1 billion U.S. federal funding award.

Here’re the key catalysts for the unfolding week:

Conferences

72nd National Hemophilia Foundation’s Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8

PDUFA Dates

FDA is scheduled to rule on DBV TECHNOLOGIE/S’ ADR (NASDAQ: DBVT) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through.

Trevena Inc (NASDAQ: TRVN) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.

FDA is also due to rule on Eagle Pharmaceuticals Inc’s (NASDAQ: EGRX) exertional heat stroke drug ryanodex Saturday.

 » Read More

Leave a Reply

Your email address will not be published.

Do NOT follow this link or you will be banned from the site!
covidnews.ch